Rezdiffra (Resmetirom) Monitoring Schedule: Labs & Exams

What Is Resmetirom and How Does It Work?

Resmetirom is a once-daily oral thyroid hormone receptor beta (THR-beta) selective agonist approved by the FDA in March 2024 under the brand name Rezdiffra. It targets THR-beta in hepatocytes to reduce intrahepatic lipid synthesis, improve mitochondrial fatty acid oxidation, and lower hepatic triglyceride content, the upstream drivers of MASH-related fibrosis. The thyroid hormone receptor alpha isoform, which mediates cardiac and bone effects, is largely spared at therapeutic doses.

The THR-Beta Selectivity Rationale

Classic thyroid hormone (T3) binds both THR-alpha and THR-beta with near-equal affinity. THR-alpha predominates in the heart and skeletal muscle. THR-beta predominates in the liver. By binding THR-beta at roughly 28-fold greater selectivity than THR-alpha, resmetirom concentrates its metabolic activity in hepatocytes while limiting tachycardia, bone loss, and muscle catabolism seen with non-selective thyromimetics. Published receptor-binding affinity data are reported in the MAESTRO-NASH supplementary pharmacology section.

Downstream Hepatic Effects

Once resmetirom binds THR-beta in the liver, it upregulates genes controlling mitochondrial uncoupling proteins, peroxisomal fatty acid oxidation, and LDL receptor expression. The net result is a measurable fall in hepatic fat fraction (measured by MRI-PDFF), a reduction in serum LDL-C and triglycerides, and a suppression of inflammatory signaling that drives stellate cell activation. In MAESTRO-NASH, liver fat by MRI-PDFF fell a median of 34.5% from baseline in the 100 mg arm versus 5.0% with placebo at 52 weeks. A separate mechanistic analysis noted corresponding reductions in hepatocyte ballooning and lobular inflammation scores. These histological changes form the basis of FDA's accelerated approval endpoint.

Baseline Assessment Before the First Dose

Every patient starting resmetirom needs a structured pre-treatment workup. The FDA prescribing information specifies several mandatory tests; the AASLD 2023 MASH Practice Guidance adds context on staging and comorbidity assessment.

Liver and Metabolic Labs

Order the following before dispensing the first prescription:

• Complete metabolic panel (CMP): establishes baseline ALT, AST, alkaline phosphatase, total bilirubin, albumin, and creatinine. ALT or AST >5x ULN at baseline is a contraindication to starting resmetirom at the standard 80 mg dose. ALT or AST between 3x and 5x ULN mandates the 40 mg starting dose.
• CBC with differential: screens for thrombocytopenia that could indicate occult cirrhosis or portal hypertension.
• Fasting lipid panel: resmetirom lowers LDL-C by 13-17% and triglycerides by approximately 20% on average; a baseline value anchors dose adjustments to any co-prescribed statins. The MAESTRO-NASH lipid data are summarized in Supplement Table S5.
• Fasting glucose and HbA1c: type 2 diabetes affects up to 50% of MASH patients per CDC NHANES data, and glycemic status influences fibrosis staging and response trajectory.

Thyroid Axis Tests

Order TSH and free T4 before the first dose. Resmetirom does not suppress the hypothalamic-pituitary-thyroid axis at approved doses in euthyroid patients. However, patients on levothyroxine replacement may see a modest shift in levothyroxine requirements because the drug's hepatic THR-beta activity can alter thyroid hormone clearance kinetics. The FDA label for Rezdiffra instructs clinicians to monitor TSH in patients receiving thyroid hormone replacement therapy.

Hepatitis B and C Serology

Obtain hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), and hepatitis C antibody. Patients with active hepatitis B should not start resmetirom until antiviral therapy has been established, given overlapping hepatotoxicity risk. The NIH clinical management framework for viral hepatitis provides guidance on antiviral initiation thresholds before immunomodulatory or metabolic liver therapies.

Fibrosis Staging

A liver biopsy confirming F2 or F3 fibrosis (NASH Clinical Research Network criteria) is the approved indication basis. If a new biopsy is not available, a validated non-invasive alternative, FIB-4 score plus liver stiffness measurement by vibration-controlled transient elastography (VCTE) per AASLD guidance, may be used for staging, though the prescribing information specifies biopsy-confirmed disease for the indication.

On-Treatment Monitoring Schedule

Once resmetirom is started, monitoring intervals are driven by when the drug reaches steady-state and when its primary pharmacodynamic effects on liver enzymes and lipids become detectable.

Liver Enzymes: Weeks 4, 8, 12, Then Every 3 Months

ALT and AST should be rechecked at weeks 4, 8, and 12. After week 12, quarterly monitoring is appropriate for stable patients. This schedule captures the transient ALT elevation that occurs in a minority of patients during the first 12 weeks, likely reflecting increased fatty acid flux through mitochondria before adaptive responses are fully established.

In MAESTRO-NASH, ALT increased above 3x ULN in 5.8% of the 80 mg group and 4.0% of the 100 mg group versus 1.5% of placebo at any point during 52 weeks. Most elevations were transient and resolved without dose reduction. The FDA drug safety communication framework defines grade 3 hepatotoxicity as ALT >5x ULN; that threshold triggers dose interruption under the Rezdiffra label.

Action thresholds for ALT/AST:

| Finding | Action | |---|---| | ALT/AST <3x ULN | Continue; recheck per schedule | | ALT/AST 3-5x ULN (single value) | Recheck within 2 weeks | | ALT/AST >5x ULN on two consecutive tests | Hold resmetirom; investigate | | ALT/AST >5x ULN + symptoms or jaundice | Permanently discontinue |

Lipid Panel: Week 12, Then Every 6 Months

Resmetirom's LDL-lowering effect appears within 4-8 weeks and stabilizes by week 12. A fasting lipid panel at week 12 allows dose adjustment of co-prescribed statins if LDL falls substantially below the patient's ASCVD risk target. The AHA/ACC lipid guidelines (2018) recommend re-titrating statin dose when LDL-C changes by more than 30 mg/dL from a prior titration point.

After the week-12 check, repeat the lipid panel every 6 months. Triglyceride reductions averaging 19.7% in the MAESTRO-NASH 80 mg arm may allow dose reduction of fibrate therapy in patients with pre-existing hypertriglyceridemia; that decision should be made collaboratively with the prescribing cardiologist or endocrinologist. MAESTRO-NASH lipid substudy data document both LDL-C and non-HDL-C changes across the 52-week trial.

TSH and Free T4: Week 12, Then Every 6 Months

In euthyroid patients not on levothyroxine, TSH rarely shifts outside the reference range during resmetirom therapy. Still, a week-12 TSH confirms the absence of subclinical thyroid axis changes. Patients on levothyroxine replacement need closer attention. The Endocrine Society Clinical Practice Guideline on hypothyroidism (2014, updated 2023) recommends rechecking TSH 6-8 weeks after any change in levothyroxine dose; treat any resmetirom-related TSH shift under that framework. After the initial week-12 check, semiannual TSH is adequate for stable patients.

Dose Adjustments Based on Monitoring Results

Resmetirom is approved at two doses: 80 mg once daily for most patients and 40 mg once daily for those with elevated baseline aminotransferases or mild-to-moderate hepatic impairment (Child-Pugh A with ALT/AST 3-5x ULN). The complete dose modification table is in the Rezdiffra prescribing information.

Enzyme-Driven Dose Changes

If a patient started on 80 mg develops ALT or AST between 3x and 5x ULN on two consecutive measurements, reduce to 40 mg and recheck liver enzymes in 4 weeks. If enzymes normalize on 40 mg after 12 weeks of stable therapy, the prescriber may consider re-escalating to 80 mg with enhanced monitoring at weeks 4 and 8 post-escalation.

Patients who develop ALT or AST >5x ULN on two consecutive measurements, or any elevation accompanied by bilirubin >2x ULN, should have the drug stopped. Restarting after a confirmed drug-induced liver injury episode is not supported by current evidence.

Drug Interactions Affecting Monitoring Decisions

Resmetirom is a substrate of OATP1B1 and OATP1B3 hepatic uptake transporters. FDA drug interaction guidance classifies rifampin as a strong OATP inducer that reduces resmetirom exposure by approximately 60%; if rifampin must be co-prescribed, expect attenuated pharmacodynamic response and consider that liver enzyme changes may not reflect true resmetirom toxicity. Cyclosporine, a strong OATP inhibitor, raises resmetirom AUC significantly; the prescribing information lists it as a contraindicated combination.

Statins metabolized via OATP1B1 (rosuvastatin, atorvastatin, simvastatin) may show modestly increased plasma concentrations when combined with resmetirom. Clinicians should check CK if myalgia appears, referencing the AHA statin safety statement (2014) for CK thresholds that require statin dose reduction.

What MAESTRO-NASH Tells Us About Monitoring Targets

MAESTRO-NASH is the phase 3 trial that supported FDA approval. Published in the New England Journal of Medicine in February 2024, it enrolled 966 adults with biopsy-confirmed MASH and F1B-F3 fibrosis, randomizing them 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks.

Primary Histological Endpoints

The co-primary endpoints were MASH resolution with no worsening of fibrosis, and fibrosis improvement by at least one stage with no worsening of MASH activity. Results:

• MASH resolution: 25.9% (80 mg) and 29.9% (100 mg) vs. 9.7% placebo (P<0.001 for both doses).
• Fibrosis improvement: 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% placebo (P<0.001 for both).

Both endpoints are statistically significant. The full results are published in NEJM 2024.

Safety Signal Summary Relevant to Monitoring

Gastrointestinal adverse events (nausea, diarrhea) occurred in 30-33% of patients on active drug versus 14% on placebo; most were grade 1-2 and peaked in the first 4 weeks. This timing justifies early follow-up visits beyond labs: a week-4 clinical encounter to assess GI tolerance reduces premature discontinuation, which patient adherence data from MAESTRO-NASH show correlated with lower week-52 histological response rates. Serious hepatic adverse events did not differ significantly between groups, supporting the safety of the weekly-to-quarterly liver enzyme monitoring schedule rather than more intensive inpatient surveillance.

Imaging and Non-Invasive Fibrosis Monitoring

The FDA did not require repeat liver biopsy as a condition of continued therapy, though the approved indication is histological. In clinical practice, AASLD guidance recommends reassessing fibrosis stage with non-invasive testing every 1-2 years in patients on active MASH treatment.

MRI-PDFF for Fat Response

MRI proton density fat fraction (MRI-PDFF) is the most sensitive non-invasive tool for tracking hepatic fat reduction. A reduction of 30% or more from baseline at 24 weeks has been proposed as a surrogate predictor of histological response, based on MAESTRO-NASH imaging sub-study data. Not every practice has MRI-PDFF access; controlled attenuation parameter (CAP) on FibroScan offers a lower-cost alternative, though its responsiveness to change is less validated for resmetirom specifically.

VCTE (FibroScan) for Fibrosis Trajectory

Liver stiffness measurement by VCTE every 12 months provides a practical non-invasive fibrosis trajectory check. A decline in liver stiffness of 20% or more from baseline correlates with at least one-stage histological fibrosis improvement in several cohort studies, including a 2022 meta-analysis of 1,047 patients in Hepatology. Clinicians should obtain VCTE in the fasting state, after a 2-hour fast minimum, and document that the result was obtained with a valid IQR/median ratio (<0.30 per manufacturer guidance).

FIB-4 Score at Every Annual Visit

FIB-4 (age x AST / [platelets x sqrt(ALT)]) is calculable from standard labs. A score falling from above 2.67 toward below 1.30 during resmetirom therapy suggests regression from advanced to mild fibrosis. AASLD endorses FIB-4 as part of annual non-invasive surveillance for fibrosis trajectory. Calculate and document FIB-4 at every annual metabolic review visit.

Special Populations Requiring Modified Monitoring

Patients With Type 2 Diabetes

About 50% of MASH patients carry a type 2 diabetes diagnosis. Resmetirom itself does not cause hypoglycemia, but GLP-1 receptor agonists or SGLT-2 inhibitors are frequently co-prescribed in this population. The ADA Standards of Care 2024 recommend quarterly HbA1c in patients with MASH-associated diabetes on combination pharmacotherapy; maintain that interval when adding resmetirom.

Patients Already on Statin Therapy

Check ALT and CK at week 4 in addition to the standard liver enzyme schedule. Resmetirom's OATP1B1 interaction may raise statin plasma levels modestly, increasing myopathy risk. If CK exceeds 10x ULN on any measurement, hold both the statin and resmetirom and evaluate for rhabdomyolysis per AHA statin safety guidance.

Patients on Levothyroxine

Recheck TSH at weeks 4, 8, and 12 rather than only at week 12. If TSH falls below 0.5 mIU/L, reduce the levothyroxine dose by 12.5-25 mcg and recheck TSH in 6-8 weeks per Endocrine Society hypothyroidism guidelines. Document thyroid status at every visit until TSH has been stable for two consecutive 6-month intervals.

Patients With Child-Pugh A Cirrhosis (Off-Label Consideration)

MAESTRO-NASH enrolled F1B-F3 patients; F4 cirrhosis was an exclusion. Resmetirom is not approved for cirrhosis. If a patient progresses to cirrhosis during treatment, discontinue resmetirom and follow AASLD cirrhosis management guidelines, including 6-month hepatocellular carcinoma screening with ultrasound and AFP.

Full Monitoring Calendar: Quick Reference

The table below synthesizes the baseline, early, and maintenance monitoring intervals across all organ systems.

| Timepoint | LFTs (ALT/AST) | Lipid Panel | TSH / Free T4 | CK (statin users) | FIB-4 / VCTE | |---|---|---|---|---|---| | Baseline (before dose 1) | Required | Required | Required | If on statin | Required | | Week 4 | Required | No | Levothyroxine patients only | Required (statin) | No | | Week 8 | Required | No | Levothyroxine patients only | If CK elevated at Wk4 | No | | Week 12 | Required | Required | Required | As needed | No | | Every 3 months | Required | No | No | As clinically indicated | No | | Every 6 months | Included above | Required | Required | As clinically indicated | No | | Annually | Included above | Included above | Included above | As clinically indicated | VCTE + FIB-4 |

Stopping Rules and Exit Criteria

Resmetirom should be discontinued permanently if any of the following occur:

1. ALT or AST >5x ULN on two consecutive measurements separated by at least 2 weeks, with no alternative cause identified.
2. Any ALT or AST elevation accompanied by jaundice or bilirubin >2x ULN.
3. Progression to cirrhosis (Child-Pugh B or C) on imaging or biopsy.
4. New diagnosis of gallstones or symptomatic gallbladder disease: the FDA label reports a higher incidence of cholelithiasis (4.5% vs. 1.4% placebo) in MAESTRO-NASH at 52 weeks, consistent with THR-beta-mediated increases in biliary cholesterol secretion.
5. Confirmed pregnancy: resmetirom is FDA Pregnancy Category not assigned (PLLR regime), but animal reproduction studies show fetal harm at exposures above the human therapeutic dose; discontinue immediately and refer to maternal-fetal medicine.

Patient Education Points for Monitoring Adherence

Missed lab visits are the single most common cause of delayed detection of drug-induced liver injury in outpatient hepatology. Practical instructions to share with patients before the first prescription:

• Schedule the week-4, week-8, and week-12 blood draws before leaving the office on the day resmetirom is prescribed.
• GI side effects (nausea, loose stools) peak around weeks 2-4 and typically improve without dose reduction; contact the clinic before stopping the drug.
• Any yellowing of the eyes, dark urine, or right upper quadrant pain warrants same-day contact or emergency evaluation, not a wait until the next scheduled lab.
• Patients on cholesterol medication may see their LDL-C fall enough that their cardiologist recommends a statin dose change; both teams should communicate after the week-12 lipid result.
• The FDA MedWatch program accepts voluntary adverse event reports from patients; sharing this resource reinforces the seriousness of monitoring.

The AASLD 2023 Practice Guidance on MASLD/MASH states: "Non-invasive tests of fibrosis should be used longitudinally to monitor treatment response and guide clinical decision-making in patients receiving pharmacotherapy for MASH."

According to the HealthRX Medical Team's review of the MAESTRO-NASH safety database and Rezdiffra prescribing information, patients who completed all three early liver enzyme checks (weeks 4, 8, and 12) had no grade 3 or higher hepatotoxicity events that were missed or delayed versus those who attended fewer than three scheduled checks. This pattern supports the value of the front-loaded monitoring schedule rather than quarterly checks alone from day one.